The Use of Near-Infrared (NIR) Spectroscopy for Raw Material Identification by a Contract Pharmaceutical Manufacturer

Importance of the Topic

Near-infrared (NIR) spectroscopy is increasingly used in pharmaceutical raw material identification to meet Good Manufacturing Practice (GMP) requirements while reducing laboratory workload, accelerating turnaround and cutting operational cost. For a contract manufacturer handling a growing diversity and volume of active pharmaceutical ingredients (APIs) and excipients, rapid, non-destructive, and multi-component screening methods such as FT-NIR provide a practical way to ensure material identity, traceability and regulatory compliance without sacrificing throughput.

Objectives and Study Overview

This case study documents how Abiogen Pharma S.p.A., a medium-sized pharmaceutical manufacturer in Pisa, Italy, replaced slow, single-technique identification of incoming raw materials with a consolidated FT-NIR approach. Objectives included reducing time and cost per identification event, avoiding the need to hire additional analysts, streamlining warehouse workflows, and maintaining GMP-compliant documentation and validation practices. The instrument chosen was the Thermo Scientific Antaris FT-NIR analyzer.

Methodology and Implementation

• Instrument selection: Abiogen selected the Antaris FT-NIR for its suitability to identify multiple raw materials with a single analyzer and for vendor support and training services.
• Placement options evaluated: analyzer in raw materials warehouse (no sampling required), dispensing area (no sampling but disrupts flow), or QC laboratory (specialized analysts but requires sampling and material transfer). Abiogen placed the Antaris in the raw materials warehouse to minimize sampling, reduce turnaround time and analyze materials on arrival.
• Library creation: an initial spectral library of ~10–11 APIs and excipients was created and is continually expanded to cover incoming materials.
• Qualification and validation: instrument installation, operator training, and a site-specific validation protocol were executed. An instrument supervisor runs validation samples per Abiogen’s rigorous protocol to satisfy GMP requirements.
• Operational model: warehouse staff perform routine checks after training; a nominated instrument manager and QC oversight ensure compliance and assay integrity.

Instrumentation Used

• Thermo Scientific Antaris FT-NIR analyzer (primary instrument for raw material identification).
• Existing laboratory instruments mentioned for context: Nicolet FT-IR spectrometer and Evolution UV-Visible spectrophotometer (used previously for specific methods).

Main Results and Discussion

• Throughput and workload: Abiogen experienced a marked rise in the number and diversity of incoming raw material batches over five years. For example, Metformin Hydrochloride containers rose from 1,456 to 4,380 annually (2001 to 2006), and corresponding traditional analytical hours increased from 364 to 1,095 hours.
• Time savings with NIR: The Antaris reduced identification time per container substantially because direct, non-destructive analysis in the warehouse eliminates the need for sampling and time-consuming single-technique assays. For Metformin HCl the yearly hours using NIR were reduced to about 128–146 hours in later years versus 966–1,095 hours for traditional methods, representing major productivity gains.
• Return on investment: Abiogen calculated payback of the Antaris acquisition within approximately 18 months driven by reduced analyst hours, elimination of multiple analytical methods per material, and reduced organizational overhead.
• Regulatory compliance: NIR implementation was aligned with guidance from European Pharmacopoeia, EMEA notes on NIR, and USP recommendations. Site-specific validation and operator training supported GMP requirements for equipment qualification, documented procedures and traceability.
• Operational trade-offs: Locating the analyzer in the warehouse optimized throughput but required robust training and an instrument supervisor to offset the lack of specialized analysts on-site. Alternative strategies such as larger container sizes or vendor self-qualification were reviewed but rejected due to logistical constraints and supplier requalification burdens.

Benefits and Practical Applications

• Time and cost efficiency: consolidated NIR screening replaced multiple analytical techniques, lowering per-container identification time and total labor hours.
• Improved workflow: in-warehouse analysis of incoming shipments minimized material handling, transportation to QC labs and associated delays.
• Scalability: the spectral library approach enables rapid onboarding of new raw materials and expansion of the tested material set as procurement diversity grows.
• Compliance and documentation: validated NIR methods and a supervised operational model ensured data traceability and alignment with GMP guidance and pharmacopoeial recommendations.
• Human resources: avoided hiring additional analysts despite increased material volumes, reallocating skilled staff to higher-value laboratory tasks.

Future Trends and Applications

• Distributed spectroscopy: placing additional FT-NIR units at different points in production and supply-chain nodes to further reduce sampling steps, accelerate release decisions, and decentralize identity testing.
• Advanced chemometrics and machine learning: improved classification, multicomponent quantitation and robust adulterant detection as spectral libraries grow and models incorporate more diverse matrices and process variations.
• Integration with manufacturing execution systems (MES) and digital records: automatic logging of identity checks to support complete electronic traceability and faster batch release.
• Supplier collaboration and at-source qualification: harmonizing spectral libraries with key vendors to support vendor-managed inventory controls and reduce incoming inspection for trusted suppliers.
• Regulatory adoption: continued alignment with pharmacopeial and regulatory guidance will broaden acceptance of NIR for identity testing and potentially partial assay or in-process controls.

Conclusion

Abiogen’s implementation of the Antaris FT-NIR analyzer demonstrates how FT-NIR can replace slow, multi-technique raw material identification workflows while maintaining GMP compliance. Key outcomes included a substantial reduction in analyst hours, an 18-month payback on the instrument, improved warehouse throughput and the ability to scale identification capacity with a growing range of APIs and excipients. Success relied not only on instrument performance but also on structured validation, a maintained spectral library, targeted operator training and a governance model assigning instrument supervision.

References

• Chapter 5.30, Good Manufacturing Practice (GMP) guidelines.
• EMEA, Note for Guidance on the Use of Near-Infrared Spectroscopy by the Pharmaceutical Industry and the Data Requirements for New Submissions and Variations (CPMP/QWP/3309/01; EMEA/CVMP/961/01), 2003.
• European Pharmacopoeia 5, 2005.
• United States Pharmacopeia (USP) 29, 2006.